NeoLAB® Solid Tumor Liquid Biopsy | NeoGenomics Laboratories

The NeoLAB Solid Tumor Liquid Biopsy is a next-gen sequencing assay designed to detect mutations in cell-free circulating tumor DNA of patients with solid tumors (pan-cancer). Analytic validation demonstrated accuracy of 98.0%, sensitivity of 95.1%, and specificity of 98.8%.

SNVs and indels (969 mutations across these 44 genes): AKT1, ALK, APC, AR, ARAF, BRAF, CHEK2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (aka MEK1), MAP2K2 (aka MEK2), MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SF3B1, SMAD4, SMO, and TP53.

NOTE: Not available for samples from New York.

Orderable Turn Around Time

7 to 10 Days

Keywords

Meta Description

<p>NeoLAB® Solid Tumor Liquid Biopsy is a highly sensitive and specific plasma-based test detecting cell-free ctDNA in patients with solid tumor cancers.</p>

Orderable Biomarkers

NY Approved

False

Orderable Biomarkers JSON

{"DNA Sequencing": {"SNVs + Indels": ["HRAS", "IDH1", "IDH2", "KIT", "KRAS", "NRAS", "FBXW7", "SF3B1", "MAP2K1", "STK11", "MAP2K2", "ALK", "AR", "ARAF", "MTOR", "RAF1", "RET", "CDKN2A", "DDR2", "ROS1", "AKT1", "ERBB3", "FGFR2", "FGFR3", "FLT3", "CHEK2", "CTNNB1", "EGFR", "ERBB2", "FGFR4", "ESR1", "NTRK1", "FGFR1", "MET", "SMO", "NTRK3", "GNA11", "PDGFRA", "PIK3CA", "GNAS", "GNAQ", "PTEN", "SMAD4", "TP53", "APC", "BRAF"]}}

Keywords string

Oncomine, plasma testing, plasma test, ctDNA, cfDNA, CTC, ct-DNA, cf-DNA, cf DNA, ct DNA, liquid bx NeoLAB® Solid Tumor Liquid Biopsy

Title URL

neolab-solid-tumor-liquid-biopsy